Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05759572 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started2023-03-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-17
notable
Enrollment closed, study ongoing
Primary completion 2026-07-21, at least 262 days after the final estimate of 2025-11-01
Completion pushed: 2027-06-01 → 2027-07-01
2024-02-04
minor
Study Identification, Study Status v2
Re-verified, no change to tracked fields
2023-05-07
minor
Study Status, Sponsor/Collaborators, Conditions v1
Collaborators+470 characters
Peking University Cancer Hospital & Institute First Hospital of China Medical University Sun Yat-sen University First Affiliated Hospital Xi'an Jiaotong University Liaoning Cancer Hospital & Institute Chongqing University Cancer Hospital Northern Jiangsu People's Hospital Fujian Medical University U [...]
2023-02-26
minor
Original filing
624 trials monitored
See 9 trials at risk
5,180 trials monitored
See 256 trials at risk
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Trial Details
NCT Number NCT05759572
Lead Sponsor Fudan University
Collaborators: Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-Sen University Cancer Center, First Affiliated Hospital Xi'an Jiaotong University, Liaoning Cancer Hospital & Institute, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Affiliated Hospital of Nantong University, The Third Affiliated Hospital of Nanchang University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University
Conditions Breast Cancer Metastatic
Enrollment 145 participants
Start Date 2023-03-01
Primary Completion 2026-07-21 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-16